Sawai Group Holdings is scheduled to receive a dividend of 832 million yen from its consolidated subsidiary Sawai Pharmaceutical, which will be recorded in the individual financial statements for the fiscal year ending March 2027. It will not affect consolidated performance.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4887","jir_company_name":"Sawai Group Holdings Co., Ltd.","jir_importance":"\u2605\u2605\u2606\u2606\u2606","jir_publication_date":"2026-05-22","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/4887-20260522-01.pdf","jir_short_summary":"Sawai Group Holdings is scheduled to receive a dividend of 832 million yen from its consolidated subsidiary Sawai Pharmaceutical, which will be recorded in the individual financial statements for the fiscal year ending March 2027. It will not affect consolidated performance.","jir_summary":"### Performance Overview\nSawai Group Holdings is scheduled to receive a dividend of 832 million yen from its consolidated subsidiary Sawai Pharmaceutical. The dividend will be received on July 31, 2026, and is expected to be recorded as Receipt of Dividends from Affiliates in operating revenue in the individual financial statements for the fiscal year ending March 2027. However, it will not impact the consolidated results. This dividend receipt is positioned as a stable income source from a subsidiary and contributes to financial soundness and improved capital efficiency.\n\n### Impact on Shareholders and Future Outlook\nThis dividend receipt does not directly affect dividends or shareholder returns, but it strengthens the company\u2019s financial base as stable income from a subsidiary. Going forward, the company will continue to monitor subsidiary performance and dividend policies, aiming to maintain financial health and enhance capital efficiency. For investors, securing stable dividend income from affiliated companies is seen as contributing to corporate value improvement.","jir_financial_highlights":"Total Dividends: 832 million yen (Unknown)\nScheduled Receipt Date: July 31, 2026 (Unknown)","jir_category":"","jir_hashtags":"#SawaiGroupHoldings, #FinancialResults, #JapaneseStocks","jir_key_figures":"Total Dividends: 832 million yen\nScheduled Receipt Date: July 31, 2026\nTo be recorded in the individual financial statements for the fiscal year ending March 2027","jir_meta_title":"\u3010Sawai Group Holdings\u3011Dividend Receipt from Subsidiary | July 2026","jir_meta_description":"Sawai Group Holdings is scheduled to receive a dividend of 832 million yen from its consolidated subsidiary Sawai Pharmaceutical. It will be recorded in the individual financial statements for the fiscal year ending March 2027, strengthening financial stability.","jir_og_title":"\u3010Sawai Group\u3011Notice of Dividend Receipt from Subsidiary | July 2026","jir_og_description":"Scheduled to receive a dividend of 832 million yen from a consolidated subsidiary in July 2026. Contributing to financial stabilization and corporate value enhancement.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":8760,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-54069","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n